Limits...
An International Survey of Health Care Providers Involved in the Management of Cancer Patients Exposed to Cardiotoxic Therapy.

Sulpher J, Mathur S, Lenihan D, Johnson C, Turek M, Law A, Stadnick E, Dattilo F, Graham N, Dent SF - J Oncol (2015)

Bottom Line: However, only 36% of total respondents agreed with an accepted definition of cardiotoxicity.Although results confirm a high level of concern for cardiac safety, there continues to be a lack of consensus on the definition of cardiotoxicity and a discrepancy in clinical practice between cardiologists and oncologists.These differences in opinion require resolution through more effective research collaboration and formulation of evidence-based guidelines.

View Article: PubMed Central - PubMed

Affiliation: The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada K1H 8L6.

ABSTRACT
Cardiotoxicity is the second leading cause of morbidity and mortality in cancer survivors. The objective of this international cardiac oncology survey was to gain a better understanding of current knowledge and practice patterns among HCPs involved in the management of cancer patients exposed to potentially cardiotoxic drugs. Between 2012 and 2013, we conducted an email-based survey of HCPs involved in the management of cardiac disease in cancer patients. 393 survey responses were received, of which 77 were from Canadian respondents. The majority of respondents were cardiologists (47%), followed closely by medical oncologists. The majority of respondents agreed that cardiac issues are important to cancer patients (97%). However, only 36% of total respondents agreed with an accepted definition of cardiotoxicity. While 78% of respondents felt that cardiac medications are protective during active cancer treatment, only 51% would consider prescribing these medications up-front in cancer patients. Although results confirm a high level of concern for cardiac safety, there continues to be a lack of consensus on the definition of cardiotoxicity and a discrepancy in clinical practice between cardiologists and oncologists. These differences in opinion require resolution through more effective research collaboration and formulation of evidence-based guidelines.

No MeSH data available.


Related in: MedlinePlus

Are cardiac medications protective during active treatment? CCON results (n = 77).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4537762&req=5

fig2: Are cardiac medications protective during active treatment? CCON results (n = 77).

Mentions: The majority of respondents agreed that cardiac issues are important to cancer patients (381/393, 97%). Ninety-four percent felt that the diagnosis of cardiac disease had an impact on cancer prognosis (349/383) and 77% agreed that chemotherapy or radiation is an important risk factor for cardiac disease (301/393). However, only 36% of total respondents agreed with an accepted definition of cardiotoxicity (109/383). The majority of Canadian cardiologists felt that there is no formal definition of cardiotoxicity, while the majority of Canadian oncologists felt that there was an established definition (Figure 1). In spite of the high percentage (78%) of respondents who felt that cardiac medications are protective during active treatment (307/393), only 51% would consider prescribing these medications up-front in cancer patients (199/393). A large percentage of Canadian respondents answered “not sure” (29/77, 38%) to the protective effect of cardiac medications (Figure 2) and “not sure” (25/77, 32%) as to whether they would use them in clinical practice (Figure 3).


An International Survey of Health Care Providers Involved in the Management of Cancer Patients Exposed to Cardiotoxic Therapy.

Sulpher J, Mathur S, Lenihan D, Johnson C, Turek M, Law A, Stadnick E, Dattilo F, Graham N, Dent SF - J Oncol (2015)

Are cardiac medications protective during active treatment? CCON results (n = 77).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4537762&req=5

fig2: Are cardiac medications protective during active treatment? CCON results (n = 77).
Mentions: The majority of respondents agreed that cardiac issues are important to cancer patients (381/393, 97%). Ninety-four percent felt that the diagnosis of cardiac disease had an impact on cancer prognosis (349/383) and 77% agreed that chemotherapy or radiation is an important risk factor for cardiac disease (301/393). However, only 36% of total respondents agreed with an accepted definition of cardiotoxicity (109/383). The majority of Canadian cardiologists felt that there is no formal definition of cardiotoxicity, while the majority of Canadian oncologists felt that there was an established definition (Figure 1). In spite of the high percentage (78%) of respondents who felt that cardiac medications are protective during active treatment (307/393), only 51% would consider prescribing these medications up-front in cancer patients (199/393). A large percentage of Canadian respondents answered “not sure” (29/77, 38%) to the protective effect of cardiac medications (Figure 2) and “not sure” (25/77, 32%) as to whether they would use them in clinical practice (Figure 3).

Bottom Line: However, only 36% of total respondents agreed with an accepted definition of cardiotoxicity.Although results confirm a high level of concern for cardiac safety, there continues to be a lack of consensus on the definition of cardiotoxicity and a discrepancy in clinical practice between cardiologists and oncologists.These differences in opinion require resolution through more effective research collaboration and formulation of evidence-based guidelines.

View Article: PubMed Central - PubMed

Affiliation: The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada K1H 8L6.

ABSTRACT
Cardiotoxicity is the second leading cause of morbidity and mortality in cancer survivors. The objective of this international cardiac oncology survey was to gain a better understanding of current knowledge and practice patterns among HCPs involved in the management of cancer patients exposed to potentially cardiotoxic drugs. Between 2012 and 2013, we conducted an email-based survey of HCPs involved in the management of cardiac disease in cancer patients. 393 survey responses were received, of which 77 were from Canadian respondents. The majority of respondents were cardiologists (47%), followed closely by medical oncologists. The majority of respondents agreed that cardiac issues are important to cancer patients (97%). However, only 36% of total respondents agreed with an accepted definition of cardiotoxicity. While 78% of respondents felt that cardiac medications are protective during active cancer treatment, only 51% would consider prescribing these medications up-front in cancer patients. Although results confirm a high level of concern for cardiac safety, there continues to be a lack of consensus on the definition of cardiotoxicity and a discrepancy in clinical practice between cardiologists and oncologists. These differences in opinion require resolution through more effective research collaboration and formulation of evidence-based guidelines.

No MeSH data available.


Related in: MedlinePlus